Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681275 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
A Phase 2 study of Diaphragm Injury, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT03681275 is a Phase 2 study of Diaphragm Injury that is actively recruiting participants, run by Stanford University. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03681275, a Phase 2 study of Diaphragm Injury, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Conditions Studied
Interventions
- DRUG Tofacitinib 10 MG [Xeljanz]
- DRUG Placebo to match Tofacitinib
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681275
The ClinicalTrials.gov registry entry for NCT03681275 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diaphragm Injury appearing as the primary indexed condition, and to 2 interventions - of which Tofacitinib 10 MG [Xeljanz] is the first listed.
NCT03681275 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03681275 about?
NCT03681275 is a clinical study titled "Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction". We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of...
What is the current status of trial NCT03681275?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2019-09-03. Estimated completion is 2026-11-30.
What conditions does trial NCT03681275 study?
This clinical trial studies the following conditions: Diaphragm Injury.
What interventions are being tested in trial NCT03681275?
The interventions under investigation include: Tofacitinib 10 MG [Xeljanz] (DRUG), Placebo to match Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT03681275?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681275 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diaphragm Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.